✦ LIBER ✦

UROKINASE VERSUS TISSUE PLASMINOGEN ACTIVATOR IN PULMONARY EMBOLISM

✍ Scribed by Sasahara, ArthurA.; Henkin, Jack; Janicki, RobertS.; Stern, M.; Meyer, G.; Sors, H.; Gaffney, PatrickJ.; Thomas, DuncanP.

Book ID: 122459324
Publisher: The Lancet
Year: 1988
Tongue: English
Weight: 333 KB
Volume: 332
Category: Article
ISSN: 0140-6736
DOI: 10.1016/S0140-6736(88)90509-0

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

UROKINASE VERSUS TISSUE PLASMINOGEN ACTI

UROKINASE VERSUS TISSUE PLASMINOGEN ACTIVATOR IN PULMONARY EMBOLISM

✍ Goldhaber, SamuelZ.; Loscalzo, Joseph 📂 Article 📅 1988 🏛 The Lancet 🌐 English ⚖ 188 KB

Randomised controlled trial of recombina

Randomised controlled trial of recombinant tissue plasminogen activator versus urokinase in the treatment of acute pulmonary embolism

✍ O'Hara, Patrick J. 📂 Article 📅 1989 🏛 Elsevier Science 🌐 English ⚖ 153 KB

Recombinant tissue-type plasminogen acti

Recombinant tissue-type plasminogen activator versus a novel dosing regimen of urokinase in acute pulmonary embolism: a randomized controlled multicenter trial

✍ Samuel Z. Goldhaber; Craig M. Kessler; John A. Heit; C.Gregory Elliott; William 📂 Article 📅 1992 🏛 Elsevier Science 🌐 English ⚖ 625 KB

Recombinant tissue plasminogen activator

Recombinant tissue plasminogen activator vs urokinase in acute pulmonary embolism

✍ Goldhaber, S.Z. 📂 Article 📅 1989 🏛 Elsevier Science 🌐 English ⚖ 103 KB

TISSUE PLASMINOGEN ACTIVATOR VERSUS UROK

TISSUE PLASMINOGEN ACTIVATOR VERSUS UROKINASE

✍ EBERS, G 📂 Article 📅 1988 🏛 The Lancet 🌐 English ⚖ 172 KB

Tissue plasminogen activator and acute p

Tissue plasminogen activator and acute pulmonary embolism

✍ Samuel Z. Goldhaber; Craig M. Kessler; John Heit; John E. Markis; G. V. R. K. Sh 📂 Article 📅 1988 🏛 John Wiley and Sons 🌐 English ⚖ 714 KB

We assessed the efficacy and safety of peripheral intravenous recombinant human tissue-type plasminogen activator (rt-PA) in 47 patients with angiographically documented pulmonary embolism (PE). We administered 50 mg/2 h and, if necessary, an additional 40 mg/4 h. By 6 hours, 94% of the patients had